EAM Investors’s Emergent Biosolutions EBS Stock Holding History

EAM Investors’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-17,047	Closed	-$1.76M	–	320
2020 Q3	$1.76M	Buy	+17,047	New	+$1.84M	0.42%	74
2019 Q1	–	Sell	-32,808	Closed	-$1.95M	–	271
2018 Q4	$1.95M	Sell	32,808 -22,715	-41%	-$1.46M	0.53%	51
2018 Q3	$3.65M	Buy	+55,523	New	+$3.24M	0.54%	47

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

EAM Investors's EBS Position: Q4 2020 in Review

EAM Investors sold out of Emergent Biosolutions (EBS) in Q4 2020, closing a stake of 17,047 shares — an estimated $1.76M sold.

EAM Investors first reported a position in EBS in Q3 2018 and held it in 3 quarters. The position peaked at $3.65M in Q3 2018. 353 funds tracked by Wall St. Rank hold EBS as of Q4 2020.

EAM Investors reported no remaining Emergent Biosolutions position as of Q4 2020 after selling out during the quarter.
EAM Investors sold 17,047 Emergent Biosolutions shares in Q4 2020, an estimated $1.76M.
EAM Investors first reported a position in Emergent Biosolutions in Q3 2018 and held it in 3 quarters.
EAM Investors's Emergent Biosolutions position peaked at $3.65M in Q3 2018.
353 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2020.

Based on EAM Investors's 13F filing for Q4 2020, filed 11 Feb 2021.